Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
LUCDRecognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer...
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
LUCD(NASDAQ:LUCD) NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten...
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
LUCDFireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
LUCDLucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid or the Company), a...
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $7.75
LUCDLucid Diagnostics Files For Offering Of 36M Shares Of Common Stock
LUCDLucid Diagnostics May Offer Sell Shares Of Common Stock Of Up To $25M
LUCDLucid Diagnostics to Join Russell 2000 And Russell 3000 Indexes On Jun. 27
LUCDCantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $2 Price Target
LUCDNeedham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target
LUCDLucid Diagnostics Q1 Adj. EPS $(0.16), Inline, Sales $800.00K Miss $1.28M Estimate
LUCDA Glimpse of Lucid Diagnostics's Earnings Potential
LUCDLucid Diagnostics Announces Data From A National Cancer Institute Sponsored Study Demonstrating EsoGuard Can Detect Esophageal Precancer Among At-Risk Patients Without Symptoms Of GERD
LUCDAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $7.5
LUCDLucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst
LUCDA Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.
Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target
LUCDReported Earlier, Lucid Diagnostics Prices $15M Public Offering Of 12.5M Common Shares At $1.20/Share
LUCDLucid Diagnostics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
LUCDCantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $2 Price Target
LUCDNeedham Maintains Buy on Lucid Diagnostics, Raises Price Target to $3
LUCDLucid Diagnostics Q4 2024 GAAP EPS $(0.19), Inline, Sales $1.20M Miss $1.42M Estimate
LUCDLucid Diagnostics Announced NCCN Guidelines Update Endorsing Non-Endoscopic Biomarker Tests, Including EsoGuard, As Alternative To Endoscopy For Barrett's Esophagus Screening
LUCDLucid Diagnostics' ENVET-BE Clinical Utility Study Of EsoGuard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication; Study Confirms Clinical Utility Of EsoGuard As A Non-Invasive Triage Tool To Significantly Increase Yield Of Invasive Upper
LUCDLucid Diagnostics, PAVmed Reveal Positive Coverage Policy For Non-invasive Screening Of Esophageal Precancer And Cancer In New York State
LUCDLucid Diagnostics Announces $15.3M Registered Direct Offering Of 13,939,331 Shares Of Common Stock At A Purchase Price Of $1.10 Per Share
LUCDLucid Diagnostics Partners With NIH For $8M Study On Esophageal Precancer Detection Using EsoCheck And EsoGuard; 5-Year Clinical Study Involves Case Western Reserve University And University Hospitals
LUCDLucid Diagnostics Regained Compliance With Nasdaq $1 Minimum Bid Price On Feb 24
LUCDLucid Diagnostics Announces First Concierge Medicine Contract With LEAA Health, Offering EsoGuard Esophageal DNA Test For Precancer Screening
LUCDLucid Diagnostics Granted 180-Day Extension By Nasdaq To Regain Compliance With $1 Minimum Bid Price Rule, Deadline Set For June 16, 2025
LUCDLucid Diagnostics Partners With VITALExam To Expand EsoGuard Testing For Firefighters At Risk Of Esophageal Precancer, Launching With #CheckYourFoodTube Event At Tuscaloosa Fire Rescue
LUCDLucid Diagnostics Partners With VITALExam, To Enhance Access To Lucid's EsoGuard Esophageal DNA Test For Firefighters At Risk For Esophageal Precancer
LUCDLucid Diagnostics And Subsidiary Of PAVmed Announced That It Has Submitted Its Complete Clinical Evidence Package For Its Esoguard Esophageal DNA Test To Molecular Diagnostics Program Seeking Medicare Coverage For Esoguard Esophageal DNA Test
LUCDCantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $2
LUCDCanaccord Genuity Maintains Buy on Lucid Diagnostics, Maintains $3 Price Target
LUCDNeedham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
LUCDLucid Diagnostics Expands Direct Contracting Initiative With Programs Targeting Near-Term Revenue Growth For EsoGuard Test
LUCD